Related Experiment Video

Updated: Jul 18, 2026

Novel Production Protocol for Small-scale Manufacture of Probiotic Fermented Foods
08:38

Novel Production Protocol for Small-scale Manufacture of Probiotic Fermented Foods

Published on: September 10, 2016

Indian Academy of Pediatrics Consensus Guidelines for Probiotic Use in Childhood Diarrhea

Surender Kumar Yachha1, Moinak Sen Sarma2, Neelam Mohan3

  • 1Department of Pediatric Gastroenterology, Hepatology and Liver Transplantation, Sakra World Hospital, Bengaluru, Karnataka. Correspondence to: Dr. Surender Kumar Yachha, Director and Head of the Department Pediatric Gastroenterology, Pediatric Hepatology and Liver Transplant; Bengaluru, Karnataka. skyachha@yahoo.co.in.

Indian Pediatrics
|March 11, 2022
PubMed

Insights

This guideline provides recommendations for probiotic use in Indian children with diarrhea. Probiotics are conditionally recommended for acute diarrhea and neonatal necrotizing enterocolitis, but not for most chronic or dysenteric conditions.

Area of Science:

  • Pediatrics
  • Gastroenterology
  • Microbiology

Background:

  • Probiotic use in childhood diarrhea lacks consistent guidelines.
  • Evolving research necessitates updated recommendations for Indian pediatric populations.

Purpose of the Study:

  • To develop evidence-based guidelines for probiotic use in pediatric diarrhea in India.
  • To consolidate current expert opinion on probiotic efficacy and safety.

Main Methods:

  • National consultative group of pediatric experts convened.
  • Comprehensive review of international and Indian literature on probiotics for diarrhea.
  • Consensus-based guideline formulation through virtual meetings and expert review.

Main Results:

  • Conditional recommendation for Lactobacillus GG or Saccharomyces boulardii in acute diarrhea.
  • Recommendation for combination probiotics in neonatal necrotizing enterocolitis (NEC).
  • No recommendation for probiotics in acute dysentery, persistent diarrhea, C. difficile, or chronic diarrheal conditions.

Conclusions:

  • Specific probiotic strains have conditional roles in acute diarrhea and NEC.
  • Probiotics are not recommended for most chronic pediatric diarrheal disorders.
  • Guidelines address probiotic use in antibiotic-associated diarrhea and pouchitis.
Abstract

More Related Videos

Probiotic Studies in Neonatal Mice Using Gavage10:36

Probiotic Studies in Neonatal Mice Using Gavage

Published on: January 27, 2019

Ginger Moxibustion, A Non-pharmacological Treatment, for Diarrhea in Patients with Chronic Obstructive Pulmonary Disease03:25

Ginger Moxibustion, A Non-pharmacological Treatment, for Diarrhea in Patients with Chronic Obstructive Pulmonary Disease

Published on: December 27, 2024

Related Concept Videos

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents01:18

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Probiotics01:22

Probiotics

Probiotics are live, non-pathogenic microorganisms that confer health benefits by modulating the gut microbiota. The human gastrointestinal tract harbors a complex microbial ecosystem, and the balance of this microbiota is crucial for digestive and systemic health. Among the most extensively studied and utilized probiotics are species formerly classified within the genera Lactobacillus and Bifidobacterium. These organisms not only naturally colonize the human gut but are also consumed through...
Microbiota Modulation by Antibiotics01:21

Microbiota Modulation by Antibiotics

Antibiotics have revolutionized modern medicine by saving countless lives from bacterial infections. However, their widespread use has inadvertently harmed the delicate balance of the human gut microbiota. The gut microbiota, a complex community of bacteria, archaea, viruses, and fungi, plays a vital role in regulating metabolism, immune responses, and maintaining intestinal health. Antibiotics, especially broad-spectrum types, disrupt this ecosystem by eradicating both harmful and beneficial...
Bacterial Gastroenteritis01:18

Bacterial Gastroenteritis

Bacterial gastroenteritis, characterized by diarrhea, abdominal cramps, and vomiting, is often caused by ingestion of contaminated food or water and is frequently associated with pathogenic Escherichia coli strains. These microbes exploit two principal mechanisms to inflict disease.Shiga toxin–producing E. coli, also referred to as STEC—notably O157:H7—release Shiga toxins that target ribosomes, blocking protein synthesis. The B subunit of the toxin binds the host glycolipid receptor...